AgomAb Therapeutics (NASDAQ:AGMB) Stock: Insider Tim Jasper Knotnerus Acquires 5,000 Shares

AgomAb Therapeutics NV (NASDAQ:AGMB) CEO Tim Jasper Knotnerus purchased 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 6th. The shares were purchased at an average cost of $8.70 per share, for a total transaction of $43,500.00. Following the purchase, the chief executive officer directly owned 21,823 shares in the company, valued at $189,860.10. This trade represents a 29.72% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Tim Jasper Knotnerus also recently made the following trade(s):

• On Monday, October 5th, Tim Jasper Knotnerus acquired 6,000 shares of AgomAb Therapeutics stock. The stock was purchased at an average price of $8.48 per share, for a total transaction of $50,880.00.

AgomAb Therapeutics Price Performance

NASDAQ:AGMB opened at $9.22 on Friday. The firm has a 50-day moving average of $12.68 and a two-hundred day moving average of $11.95. AgomAb Therapeutics NV has a 1-year low of $7.97 and a 1-year high of $17.82.

AgomAb Therapeutics (NASDAQ:AGMB) last announced its earnings results on Thursday, August 6th. The company reported ($0.46) earnings per share (EPS) for the quarter. On average, research analysts expect that AgomAb Therapeutics NV will post -1.76 EPS for the current year.

Wall Street Analysts Forecast Growth

AGMB has been the topic of a number of recent analyst reports. B. Riley Financial started coverage on AgomAb Therapeutics in a research report on Thursday, July 23rd. They issued a “buy” rating and a $34.00 target price on the stock. Piper Sandler began coverage on shares of AgomAb Therapeutics in a research note on Tuesday, August 25th. They issued an “overweight” rating and a $60.00 price target for the company. HC Wainwright reaffirmed a “buy” rating on shares of AgomAb Therapeutics in a report on Wednesday, September 16th. Wall Street Zen downgraded shares of AgomAb Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, September 27th. Finally, Cantor Fitzgerald initiated coverage on shares of AgomAb Therapeutics in a report on Wednesday, August 19th. They set an “overweight” rating for the company. Seven investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, AgomAb Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $37.50.

Key Headlines Impacting AgomAb Therapeutics

Here are the key news stories impacting AgomAb Therapeutics this week:

• Positive Sentiment: CEO Tim Jasper Knotnerus purchased 11,000 shares across October 5–6 for approximately $94,380, increasing his ownership substantially. CFO Pierre Kemula also bought 10,000 shares for about $85,900, while director David Epstein acquired 5,000 shares for $43,500. The coordinated insider buying may be viewed as a signal of management and board confidence in AgomAb’s long-term prospects. Insider Buying: AgomAb Therapeutics CEO Purchases Shares
• Positive Sentiment: AgomAb plans to present STENOVA open-label extension data for ontunisertib at UEG Week 2026 and host a scientific symposium focused on fibro-inflammation. The event could provide investors with additional information on the drug’s durability, safety and potential in inflammatory diseases. AgomAb UEG Week 2026 Presentation
• Neutral Sentiment: The planned presentation is a potential near-term catalyst, but the announcement did not include the actual clinical results. Investors will likely await the data before reassessing the program’s prospects.
• Negative Sentiment: AgomAb remains a clinical-stage biotechnology company reporting quarterly losses, with analysts expecting a full-year loss of approximately $1.76 per share. Shares are also trading below their 50-day and 200-day moving averages, reflecting continued volatility and execution risk.

AgomAb Therapeutics Company Profile

Agomab Therapeutics N.V. is a clinical-stage biotechnology company developing antibody-based medicines designed to activate biological pathways involved in tissue repair and regeneration. The company focuses on serious diseases in which restoring or rebuilding damaged tissue could provide therapeutic benefit.

Agomab’s lead program, AGMB-129, is an investigational, gut-restricted agonist of fibroblast growth factor receptor 1c (FGFR1c) being developed for inflammatory bowel disease, including Crohn’s disease.